Exploration of Hydrazide-Based HDAC8 PROTACs for the Treatment of Hematological Malignancies and Solid Tumors

被引:3
作者
Zhao, Chunlong [1 ]
Zhang, Jianqiu [1 ]
Zhou, Hangyu [1 ]
Setroikromo, Rita [1 ]
Poelarends, Gerrit J. [1 ]
Dekker, Frank J. [1 ]
机构
[1] Univ Groningen, Groningen Res Inst Pharm GRIP, Dept Chem & Pharmaceut Biol, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands
关键词
HISTONE DEACETYLASE INHIBITORS; E3 UBIQUITIN LIGASE; CELL-DEATH; PROTEIN-DEGRADATION; DISCOVERY; TARGET; COMPLEX; DESIGN; CANCER; POTENT;
D O I
10.1021/acs.jmedchem.4c00836
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
HDAC8 can mediate signals by using its enzymatic or nonenzymatic functions, which are expected to be critical for various types of cancer. Herein, we employed proteolysis targeting chimera (PROTAC) technology to target the enzymatic as well as the nonenzymatic functions of HDAC8. A potent and selective HDAC8 PROTAC Z16 (CZH-726) with low nanomolar DC50 values in various cell lines was identified. Interestingly, Z16 induced structural maintenance of chromosomes protein 3 (SMC3) hyperacetylation at low concentrations and histone hyperacetylation at high concentrations, which can be explained by HDAC8 degradation and off-target HDAC inhibition, respectively. Notably, Z16 potently inhibited proliferation of various cancer cell lines and the antiproliferative mechanisms proved to be cell-type-dependent, which, to a large extent, is due to off-target HDAC inhibition. In conclusion, we report a hydrazide-based HDAC8 PROTAC Z16, which can be used as a probe to investigate the biological functions of HDAC8.
引用
收藏
页码:14016 / 14039
页数:24
相关论文
共 67 条
  • [1] Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy
    Adhikari, Nilanjan
    Jha, Tarun
    Ghosh, Balaram
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (13) : 8827 - 8869
  • [2] The biochemical pathways of apoptotic, necroptotic, pyroptotic, and ferroptotic cell death
    Ai, Youwei
    Meng, Yutong
    Yan, Bo
    Zhou, Qinyi
    Wang, Xiaodong
    [J]. MOLECULAR CELL, 2024, 84 (01) : 170 - 179
  • [3] Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview
    Banerjee, Suvankar
    Adhikari, Nilanjan
    Amin, Sk Abdul
    Jha, Tarun
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 164 : 214 - 240
  • [4] Epigenetic Therapies for Cancer
    Bates, Susan E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (07) : 650 - 663
  • [5] PROTAC targeted protein degraders: the past is prologue
    Bekes, Miklos
    Langley, David R.
    Crews, Craig M.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (03) : 181 - 200
  • [6] Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia
    Bishton, Mark J.
    Harrison, Simon J.
    Martin, Benjamin P.
    McLaughlin, Nicole
    James, Chloe
    Josefsson, Emma C.
    Henley, Katya J.
    Kile, Benjamin T.
    Prince, H. Miles
    Johnstone, Ricky W.
    [J]. BLOOD, 2011, 117 (13) : 3658 - 3668
  • [7] Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
    Bond, Michael J.
    Chu, Ling
    Nalawansha, Dhanusha A.
    Li, Ke
    Crews, Craig M.
    [J]. ACS CENTRAL SCIENCE, 2020, 6 (08) : 1367 - 1375
  • [8] Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
    Bondeson, Daniel P.
    Smith, Blake E.
    Burslem, George M.
    Buhimschi, Alexandru D.
    Hines, John
    Jaime-Figueroa, Saul
    Wang, Jing
    Hamman, Brian D.
    Ishchenko, Alexey
    Crews, Craig M.
    [J]. CELL CHEMICAL BIOLOGY, 2018, 25 (01): : 78 - +
  • [9] Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases
    Chakrabarti, Alokta
    Melesina, Jelena
    Kolbinger, Fiona R.
    Oehme, Ina
    Senger, Johanna
    Witt, Olaf
    Sippl, Wolfgang
    Jung, Manfred
    [J]. FUTURE MEDICINAL CHEMISTRY, 2016, 8 (13) : 1609 - 1634
  • [10] HDAC8: a multifaceted target for therapeutic interventions
    Chakrabarti, Alokta
    Oehme, Ina
    Witt, Olaf
    Oliveira, Guilherme
    Sippl, Wolfgang
    Romier, Christophe
    Pierce, Raymond J.
    Jung, Manfred
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2015, 36 (07) : 481 - 492